IQVIA (NYSE:IQV) Reaches New 12-Month Low - Should You Sell?

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $135.39 and last traded at $137.00, with a volume of 890416 shares. The stock had previously closed at $137.29.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Redburn Partners set a $188.00 price target on shares of IQVIA in a research report on Friday. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird decreased their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Stock Up 3.2%

The firm's 50 day simple moving average is $154.34 and its 200-day simple moving average is $182.55. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $24.46 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's revenue was up 2.5% on a year-over-year basis. During the same period last year, the business earned $2.54 earnings per share. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently made changes to their positions in the company. American National Bank & Trust acquired a new stake in shares of IQVIA during the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd increased its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC raised its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. Synergy Asset Management LLC bought a new stake in IQVIA in the 4th quarter valued at about $33,000. Finally, AllSquare Wealth Management LLC acquired a new position in shares of IQVIA during the 1st quarter worth approximately $33,000. Institutional investors own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.